[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341461-105":59,"doc-detail-341461-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","novel-personalized-cancer-vaccine-using-tumor-extracellular-vesicles-with-attenuated-tumorigenicity-and-enhanced-immunogenicity","Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity","","Novel personalized cancer vaccination is explored using tumor extracellular vesicles (TEVs) loaded with tumor antigens, aiming to overcome TEVs’ inherent malignant properties that limit therapeutic use. The study proposes inhibiting both YAP and autophagy to attenuate malignancy-associated TEV traits while simultaneously enriching tumor antigen and adjuvant content to enhance immunogenicity. The resulting AI-TEVs show tumor growth inhibition as preventive and potential post-recurrence treatment candidates, inducing tumor-specific, durable immune memory in a personalized vaccination context.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/novel-personalized-cancer-vaccine-using-tumor-extracellular-vesicles-with-attenuated-tumorigenicity-and-enhanced-immunogenicity/341461/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/novel-personalized-cancer-vaccine-using-tumor-extracellular-vesicles-with-attenuated-tumorigenicity-and-enhanced-immunogenicity/341461.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are tumor extracellular vesicles (TEVs) attractive for cancer vaccine development?","Question",{"text":112,"@type":113},"TEVs naturally carry tumor antigens and can deliver antigenic materials to recipient cells, which can elicit tumor-specific immune responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What problem limits direct use of TEVs as anticancer therapies?",{"text":117,"@type":113},"TEVs can be involved in immunosuppressing and tumor-promoting pathways, reflecting malignant properties inherited from the original tumor cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the study enhance the immunogenicity of TEVs while reducing tumorigenicity?",{"text":121,"@type":113},"It inhibits both YAP and autophagy, which diminishes malignancy-associated traits while increasing the load of tumor antigens and adjuvants, producing attenuated yet immunogenically potentiated TEVs (AI-TEVs).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341461,1790123635,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","RESEARCH ARTICLE  \n[www.advancedscience.com](www.advancedscience.com)  \nNovel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity  \nJihoon Han, Seohyun Kim, Yeong Ha Hwang, Seong A Kim, Yeji Lee, Jihong Kim, Seongeon Cho, Jiwan Woo, Cherlhyun Jeong, Minsu Kwon, Gi-Hoon Nam, and In-San Kim*  \nCancer vaccines oﬀer a promising avenue in cancer immunotherapy by inducing systemic, tumor-speciﬁc immune responses. Tumor extracellular vesicles (TEVs) are nanoparticles naturally laden with tumor antigens, making them appealing for vaccine development. However, their inherent malignant properties from the original tumor cells limit their direct therapeutic use. This study introduces a novel approach to repurpose TEVs as potent personalized cancer vaccines. The study shows that inhibition of both YAP and autophagy not only diminishes the malignancy-associated traits of TEVs but also enhances their immunogenic attributes by enriching their load of tumor antigens and adjuvants. These revamped TEVs, termed attenuated yet immunogenically potentiated TEVs (AI-TEVs), showcase potential in inhibiting tumor growth, both as a preventive measure and a possible treatment for recurrent cancers. They prompt a tumor-speciﬁc and enduring immune memory. In addition, by showing that AI-TEVs can counteract cancer growth in a personalized vaccine approach, a potential strategy is presented for developing postoperative cancer immunotherapy that’s enduring and tailored to individual patients.  \n1. Introduction  \nDespite recent advances in surgical techniques and novel cancer therapeutic strategies, the risk of cancer recurrence remains high, posing a threat to countless patients. Therefore, it is necessary to develop a fundamental approach to eliminate residual tumors and prevent cancer recurrence by inducing systemic antitumor responses and retaining long-term memory. Personalized cancer vaccination is one of the most promising strategies for eliciting and amplifying tumor-speciﬁc immune responses designed individually, using a variety of antigens prepared directly from the patient’s tumor tissues. [1] However, to develop a successful cancer vaccine, several requirements need to be met, such as an optimal source of tumor antigensand their combination with immune adjuvants, all of which must be formulated in an  \nJ. Han, S. Kim, Y. H. Hwang, S. A Kim, Y. Lee, J. Kim, S. Cho, I.-S. Kim KU-KIST Graduate School of Converging Science and Technology Korea University  \nSeoul 02841, Republic of Korea E-mail: [iskim14@kist. re.kr](iskim14@kist. re.kr)  \nJ. Han, S. Kim, Y. H. Hwang, S. A Kim, Y. Lee, J. Kim, S. Cho, C. Jeong, I.-  \nS. Kim  \nChemical and Biomedical Integrative Research Center Korea Institute of Science and Technology (KIST) Seoul 02792, Republic of Korea  \nThe ORCID identiﬁcation number(s) for the author(s) of this article  \ncan be found under [https://doi.org/10.1002/advs.202308662](https://doi.org/10.1002/advs.202308662)[ ](https://doi.org/10.1002/advs.202308662)© 2024 The Authors. Advanced Science published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nDOI: 10.1002/advs.202308662  \nS. Kim, G.-H. Nam  \nDepartment of Research and Development ShiftBio  \nSeoul 02751, Republic of Korea  \nJ. Woo  \nResearch Animal Resource Center  \nKorea Institute of Science and Technology (KIST) Seoul 02792, Republic of Korea  \nC. Jeong  \nKHU-KIST Department of Converging Science and Technology Kyung Hee University  \nSeoul 02447, Republic of Korea  \nM. Kwon  \nDepartment of Otolaryngology Asan Medical Center  \nUniversity of Ulsan College of Medicine Seoul 05505, Republic of Korea  \nG.-H. Nam  \nDepartment of Biochemistry and Molecular Biology Korea University College of Medicine  \nSeoul 02841, Republic of Korea  \nAdv. Sci. 2024, 1","cbCaih9wtp55SQVT","https://ap.wps.com/l/cbCaih9wtp55SQVT","pdf",4240538,14,"English","# Introduction\n## Background on personalized cancer vaccination and recurrence\n## Role and limitations of tumor extracellular vesicles (TEVs)\n## Rationale for attenuating TEV malignancy and enhancing immunogenicity","[{\"question\":\"Why are tumor extracellular vesicles (TEVs) attractive for cancer vaccine development?\",\"answer\":\"TEVs naturally carry tumor antigens and can deliver antigenic materials to recipient cells, which can elicit tumor-specific immune responses.\"},{\"question\":\"What problem limits direct use of TEVs as anticancer therapies?\",\"answer\":\"TEVs can be involved in immunosuppressing and tumor-promoting pathways, reflecting malignant properties inherited from the original tumor cells.\"},{\"question\":\"How does the study enhance the immunogenicity of TEVs while reducing tumorigenicity?\",\"answer\":\"It inhibits both YAP and autophagy, which diminishes malignancy-associated traits while increasing the load of tumor antigens and adjuvants, producing attenuated yet immunogenically potentiated TEVs (AI-TEVs).\"}]","Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity | PDF",1790041982,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58ef001d400de9e13ea21cad9100f3eb.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82e73291f4c5c5aad92052843982fcb9.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0642efa21e86deb153f8d43f44a6c4ca.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8128aa8c282902916da573603444247e.webp",980,1287]